When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.
In 2023 we witnessed an incredible journey and, as we reflect on this transformative year, we can’t wait to see what 2024 will bring.
Collaborations with top-tier industry leaders
Our presence in more than 150 healthcare institutions worldwide, and our partnerships with Philips for AI oncology tools in MR and three top5 Biopharma companies, represent a fundamental step in our commitment to drive healthcare innovation. By joining forces with these market leaders, we aim to synergize knowledge, accelerate research and development, and bring cutting-edge therapies to patients around the world.
Commitment to academic excellence with 19 published papers and 3 new patents
We are seeing a remarkable surge in evidence generation. In 2023 alone, we’ve marked our presence in 19 publications, a significant increase from 12 in the previous year. It is an impressive enumeration of team-authored research and contributions from external researchers utilizing Quibim. Our presence demonstrates academic rigor is heading in the right direction. Also, we have added a new patent to our portfolio and filed 2 new applications.
Achievement of key regulatory certifications
Our QP-Brain tool has received FDA 510(k) clearance and CE and UKCA marks. This groundbreaking tool is crucial in the early detection of neurodegenerative diseases and is now available in the US, EU, and UK. QP-Brain exemplifies our commitment to enhancing patient care with innovative, secure, and data-driven approaches.
Significant milestones in European initiatives
During 2023, Quibim can proudly say that we have achieved key milestones in European healthcare initiatives. In collaboration with the EUCAIM project, we are creating a secure pan-cancer center for medical imaging data to improve early cancer detection. In addition, our participation in the RadioVal project, the first international radiological AI solution in breast cancer, is focused on validating radiomics-based chemotherapy response estimation. These are just a few examples of how our efforts contribute to the advancement of radiomic AI to improve the diagnosis and treatment of oncological diseases.
Lectures and abstracts presented at major industry conferences
As industry leaders, we understand the importance of continuous learning, networking and the exchange of innovative ideas that shape the future of healthcare. RSNA, ESMO, ECR or ASCO are influential meetings, where we not only showcase our expertise, but also gain valuable insights that enable us to improve our offering and better understand the needs of the industry.
Focus on ESG (Environmental, Social and Governance)
As part of our commitment to sustainability, this year we achieved the GPTW certification with an impressive 93 out of 100 score. It was a great recognition of our corporate principle of Just Culture, which fosters a transparent, collective decision-making environment, while our “Work from Anywhere” policy supports work-life balance. Also, we meticulously measure and track key performance indicators such as energy usage and carbon footprint. Additionally, our dedication to transparency extends to initiatives like the Corporate Whistleblower Channel and Transparency Portal, further solidifying our commitment to ethical practices and open communication.